Valneva SE (VLA) - Total Liabilities
Based on the latest financial reports, Valneva SE (VLA) has total liabilities worth €307.15 Million EUR (≈ $359.10 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See VLA defensive asset coverage days to measure how many days the company can operate on defensive assets alone.
Valneva SE - Total Liabilities Trend (2005–2025)
This chart illustrates how Valneva SE's total liabilities have evolved over time, based on quarterly financial data. Check VLA asset resilience ratio to evaluate the company's liquid asset resilience ratio.
Valneva SE Competitors by Total Liabilities
The table below lists competitors of Valneva SE ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
The Erawan Group Public Company Limited
BK:ERW
|
Thailand | ฿16.46 Billion |
|
Shenzhen Silver Basis Technology Co Ltd
SHE:002786
|
China | CN¥3.31 Billion |
|
EagleRock Land, LLC
NYSE:EROK
|
USA | $58.41 Million |
|
Shandong Molong Petroleum Machinery Co Ltd
SHE:002490
|
China | CN¥2.03 Billion |
|
Bansal Wire Industries Ltd
NSE:BANSALWIRE
|
India | Rs10.86 Billion |
|
Nanjing Hicin Pharmaceutical Co Ltd
SHE:300584
|
China | CN¥395.57 Million |
|
Kambi Group PLC Series B
LSE:0EAW
|
UK | Skr37.87 Million |
|
Shandong Shengli Co Ltd
SHE:000407
|
China | CN¥2.64 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Valneva SE's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see VLA total asset value.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.16 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 3.79 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.79 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Valneva SE's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Valneva SE (2005–2025)
The table below shows the annual total liabilities of Valneva SE from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €292.67 Million ≈ $342.16 Million |
-8.19% |
| 2024-12-31 | €318.78 Million ≈ $372.69 Million |
-3.93% |
| 2023-12-31 | €331.81 Million ≈ $387.93 Million |
-17.37% |
| 2022-12-31 | €401.55 Million ≈ $469.45 Million |
-37.92% |
| 2021-12-31 | €646.77 Million ≈ $756.14 Million |
+73.98% |
| 2020-12-31 | €371.74 Million ≈ $434.61 Million |
+186.90% |
| 2019-12-31 | €129.57 Million ≈ $151.48 Million |
+49.41% |
| 2018-12-31 | €86.72 Million ≈ $101.39 Million |
-10.30% |
| 2017-12-31 | €96.67 Million ≈ $113.02 Million |
-9.51% |
| 2016-12-31 | €106.83 Million ≈ $124.90 Million |
-18.36% |
| 2015-12-31 | €130.85 Million ≈ $152.98 Million |
+26.95% |
| 2014-12-31 | €103.07 Million ≈ $120.50 Million |
-6.54% |
| 2013-12-31 | €110.28 Million ≈ $128.93 Million |
+301.41% |
| 2012-12-31 | €27.47 Million ≈ $32.12 Million |
-15.83% |
| 2011-12-31 | €32.64 Million ≈ $38.16 Million |
-7.31% |
| 2010-12-31 | €35.21 Million ≈ $41.17 Million |
+50.31% |
| 2009-12-31 | €23.43 Million ≈ $27.39 Million |
+67.70% |
| 2008-12-31 | €13.97 Million ≈ $16.33 Million |
+32.10% |
| 2007-12-31 | €10.57 Million ≈ $12.36 Million |
+3.03% |
| 2006-12-31 | €10.26 Million ≈ $12.00 Million |
+4.48% |
| 2005-12-31 | €9.82 Million ≈ $11.48 Million |
-- |
About Valneva SE
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile t… Read more